Financial Performance - Vivani Medical reported a net loss of $25.7 million for the full year 2023, an increase of 85% compared to a net loss of $13.9 million in 2022[17]. - The net loss for the twelve months ended December 31, 2023, was $25,652,000, an increase of 84.8% from $13,889,000 in 2022[25]. - The net loss for Q4 2023 was $6,026,000, compared to a net loss of $7,284,000 in Q4 2022, representing a 17.3% improvement[25]. - The net loss per common share for Q4 2023 was $0.12, compared to $0.14 in Q4 2022[25]. - The company reported a loss from operations of $6,217,000 for Q4 2023, compared to a loss of $7,790,000 in Q4 2022[25]. Research and Development - Research and development expenses for the fourth quarter of 2023 were $4.7 million, a 6% increase from $4.4 million in the same quarter of 2022[9]. - Research and development expenses for the full year 2023 totaled $17.0 million, a 20% increase from $14.2 million in 2022[14]. - NPM-115 demonstrated approximately 20% weight loss in preclinical studies, comparable to semaglutide, after a 28-day treatment in obese mice[5]. - The company plans to submit a new Investigational New Drug Application for NPM-115 later in 2024, aiming to initiate a first-in-human trial after receiving regulatory clearance[11]. Expenses - General and administrative expenses decreased by 55% to $1.5 million in Q4 2023, down from $3.4 million in Q4 2022[10]. - General and administrative expenses for Q4 2023 were $1,509,000, a decrease of 55.2% from $3,363,000 in Q4 2022[25]. - Total operating expenses for Q4 2023 were $6,217,000, a decrease of 20.2% from $7,790,000 in Q4 2022[25]. - Total operating expenses for the twelve months ended December 31, 2023, were $26,965,000, an increase of 27.2% from $21,241,000 in 2022[25]. Financial Position - As of December 31, 2023, Vivani had cash and cash equivalents totaling $20.7 million, down from $45.1 million at the end of 2022[23]. - Total liabilities as of December 31, 2023, were $25.0 million, compared to $6.8 million at the end of 2022[23]. Corporate Developments - The company appointed Daniel Bradbury to its Board of Directors, who previously led the approval of Bydureon, a significant GLP-1 receptor agonist[4]. - The company raised $15 million in a financing round in March 2024 to accelerate development programs and fund operations into the second half of 2025[3]. Other Income - Other income for Q4 2023 was $191,000, a decrease of 62.3% from $506,000 in Q4 2022[25]. Share Information - The weighted average shares outstanding for the twelve months ended December 31, 2023, were 50,853,000, compared to 38,241,000 in 2022[25].

or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 1350 S. Loop Road, Alameda, CA 94502 (Address of principal executive of ices, including zip code) (415) 506-8462 (Registrant's telephone number, including area code) Securities registere ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-36747 Vivani Medical, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-36747 Vivani Medical, Inc. (Exact name of Registrant as specified in its charter) (State or other jurisdiction ...

Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-36747 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Vivani Medical, Inc. (Exact name of registrant as specified in its charter) California (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-36747 Second Sight Medical Products, Inc. Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR (Exact name of Registrant as specified in its charter) (State or other ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q For the transition period from ________ to ________ (818) 833-5000 Commission File Number 001-36747 Second Sight Medical Products, Inc. (Exact name of Registrant as specified in its charter) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 (State or other jurisdiction of incorporation or organization) 02-0692322 (I.R.S. Employer Identification No.) 13170 Telfair Avenue, Sylmar, CA 91342 (Address of principal executive of ices, including zip code) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHAN ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number 001-36747 Second Sight Medical Products, Inc. (Exact name of Registrant as specified in its charter) (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) (State or other jurisdiction of incorporation or organization) California 02-0692322 (I.R.S. Employer Identification No.) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File N ...